Recruitment

Recruitment Status
Completed

Inclusion Criterias

Male and female subjects aged ≥ 18 years
Clinical diagnosis of atopic dermatitis or chronic urticaria
Male and female subjects aged ≥ 18 years
Clinical diagnosis of atopic dermatitis or chronic urticaria

Summary

Conditions
Atopic Dermatitis
Type
Observational
Design
  • Observational Model: Case-Only
  • Time Perspective: Retrospective

Participation Requirements

Age
Between 18 years and 125 years
Gender
Both males and females

Description

This study will collect blood from patients of high serum IgE levels to investigate the function of h4b12, a humanized mAb specific for mIgE+ B cells, and compare the effects of h4B12, Omalizumab, and Rituxumab on the suppression of IgE production and the number of IgE-producing plasma cells. These ...

This study will collect blood from patients of high serum IgE levels to investigate the function of h4b12, a humanized mAb specific for mIgE+ B cells, and compare the effects of h4B12, Omalizumab, and Rituxumab on the suppression of IgE production and the number of IgE-producing plasma cells. These blood specimens will be collected from 50 patients of atopic dermatitis or urticaria with high serum IgE levels. Fountain Biopharma will carry out the following two in vitro assays to measure the efficacy of h4B12: IgE ELISA to determine the concentration of IgE. IgE ELISPOTto determine the number of IgE-producing plasma cells.

Inclusion Criterias

Male and female subjects aged ≥ 18 years
Clinical diagnosis of atopic dermatitis or chronic urticaria
Male and female subjects aged ≥ 18 years
Clinical diagnosis of atopic dermatitis or chronic urticaria

Locations

Taipei, 100
Taipei, 100

Tracking Information

NCT #
NCT01995747
Collaborators
Not Provided
Investigators
  • Principal Investigator: Chia-Yu Chu, M.D., Ph.D. Dept of Dermatology, NTUH
  • Chia-Yu Chu, M.D., Ph.D. Dept of Dermatology, NTUH